Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis. The Food and Drug ...

This publication was sponsored and written in partnership with Bristol Myers Squibb. This Clinical Brief provides key information on sphingosine 1-phosphate receptor modulators for relapsing forms of ...

(RTTNews) - Sandoz said that the U.S. Food and Drug Administration approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat all indications ...

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 ...

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Ublituximab-xiiy, developed by TG Therapeutics, will be sold under the name Briumvi. The FDA recently approved ublituximab-xiiy for the treatment of relapsing forms of multiple sclerosis (RMS), to ...